Phase 1 Castrate Resistant Prostate Cancer Clinical Trials
10 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–10 of 10 trials
Recruiting
Phase 1Phase 2
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals188 enrolled32 locationsNCT07206056
Recruiting
Phase 1Phase 2
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Institute of Cancer Research, United Kingdom78 enrolled4 locationsNCT07002320
Recruiting
Phase 1Phase 2
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Breast CancerColorectal, CancerGastric Cancer+10 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (CRPC)
ARTBIO Inc.80 enrolled3 locationsNCT07214961
Recruiting
Phase 1
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Triple-Negative Breast CancerGastric CancerGastroesophageal-junction Cancer+9 more
Dren Bio96 enrolled10 locationsNCT06999187
Recruiting
Phase 1
TmPSMA-02 in mCRPC
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
University of Pennsylvania30 enrolled1 locationNCT06046040
Recruiting
Phase 1
Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Jean-Mathieu Beauregard60 enrolled1 locationNCT06943495
Recruiting
Phase 1Phase 2
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
mCRPC (Metastatic Castration-resistant Prostate Cancer)Metastatic Castrate Resistant Prostate Cancer
Evopoint Biosciences Inc.307 enrolled2 locationsNCT06702995
Recruiting
Phase 1Phase 2
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Ovarian CancerEndometrial CancerNon-small Cell Lung Cancer+4 more
Portage Biotech90 enrolled3 locationsNCT04969315
Recruiting
Phase 1
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more
Epigenetix, Inc.75 enrolled6 locationsNCT05488548